Novartis (NVS) said Wednesday that the European Commission has approved its drug Kisqali in combination with an aromatase inhibitor as an adjuvant treatment for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer at high risk of recurrence.
The approval of the drug, also called ribociclib, is based on results from a 20-country, 5,101-patient phase III trial which showed a 25.1% reduction in risk of disease recurrence compared with endocrine therapy alone, the company said.
The news follows the recent US Food and Drug Administration approval of Kisqali for early breast cancer patients, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.